NCI advisors approve recompetition of $62 million phase II contracts program.
Also AIDS Malignancy Consortium grants to be consolidated on recompetition to one central group chairman’s office.
Advisors approve set-aside for alternative medicine “best case series.”
HHS bans tobacco from its campuses, opens national quitline, 1-800-QUITNOW.
Two founding cancer center directors step down: Harold Moses at Vanderbilt-Ingram and Charles Coltman at CTRC.
Funding opportunities listed.
November issue of Business & Regulatory Report, an additional 8 pages, included in this issue.
Trending Stories
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy
- Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed - Amid HHS upheaval, Bhattacharya takes the helm at NIH, Makary at FDA
Meanwhile, NASEM sounds “SOS” for health infrastructure - What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - In The Headlines: Private funding can’t replace federal funding—but it can help
